N-(5-(imidazo[1,2-a]pyridin-6-yl)thiazolo[5,4-b]pyridin-2-yl)acetamide | 1204742-02-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N-(5-(imidazo[1,2-a]pyridin-6-yl)thiazolo[5,4-b]pyridin-2-yl)acetamide
• 英文别名: N-(5-imidazo[1,2-a]pyridin-6-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide
• CAS: 1204742-02-8
• 化学式: C₁₅H₁₁N₅OS
• 分子量: 309.351
• InChiKey: ZMYCJRNDIOYCEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PI3K/mTOR INHIBITORS
  申请人：Gong Xianchang

  公开号：US20110178070A1

  公开（公告）日：2011-07-21

  The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  该发明涉及公式如下的PI3K/mTOR抑制化合物：其中变量的定义如下。该发明还涉及包括此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该化合物的方法。
• PI3K/M TOR inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2311842A2

  公开（公告）日：2011-04-20

  Compounds of the formula: wherein ring A is heteroaryl, Q is O or S; L is selected from the group consisting of -CHR3-, -NR4- and -O-; X1 and X2 are each independently selected from the group consisting of CR5, and N; and R1, R2, R3, R4, R5 and R5' are defined herein, are provided. The compounds are P13K/mTOR inhibitors and are useful in the treatment of a number of conditions, including cancer and inflammatory diseases.

  式中的化合物： 其中环 A 是杂芳基，Q 是 O 或 S；L 选自 -CHR3-、-NR4- 和 -O- 组成的组；X1 和 X2 各自独立地选自 CR5 和 N 组成的组；以及 R1、R2、R3、R4、R5 和 R5' 在此定义。这些化合物是 P13K/mTOR 抑制剂，可用于治疗多种疾病，包括癌症和炎症性疾病。
• [EN] PI3K/M TOR INHIBITORS<br/>[FR] INHIBITEURS DE PI3K/M TOR
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010008847A2

  公开（公告）日：2010-01-21

  The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula (I): wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.